Dostarlimab: A Review

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

(2022) Ming Yi et al.   Molecular Cancer

Dostarlimab for the treatment of advanced endometrial cancer

(2022) Andres Redondo et al.   Expert Review of Clinical Pharmacology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

(2022) Ana Oaknin et al.   Journal for ImmunoTherapy of Cancer

Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy

(2022) Ui Beom Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

(2022) Murad Melhem et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

(2022) Timothy A Yap et al.   Journal for ImmunoTherapy of Cancer

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey

(2022) Gaia Giannone et al.   Frontiers in Oncology

Application of histology-agnostic treatments in metastatic colorectal cancer

(2022) Andrea Sartore-Bianchi et al.   DIGESTIVE AND LIVER DISEASE

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

(2021) Ajay K Nooka et al.   Future Oncology

An Integrated Analysis of Dostarlimab Immunogenicity

(2021) Sharon Lu et al.   AAPS Journal

Dostarlimab: First Approval

(2021) Anthony Markham   DRUGS

MSI testing

(2021) Josef Rüschoff et al.   PATHOLOGE

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

(2021) Amita Patnaik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

(2021) Lucia Musacchio et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma

(2021) S. C. Sasson et al.   Scientific Reports

Regulation of PD-1 in T cells for cancer immunotherapy

(2020) Xibao Yu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors

(2020) Ole Gjoerup et al.   AAPS Journal

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

(2020) Ana Oaknin et al.   JAMA Oncology

Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer

(2020) Lawrence Kasherman et al.   Future Oncology

PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer

(2017) Francesco Sclafani   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

PD-1 and its ligands are important immune checkpoints in cancer

(2016) Yinan Dong et al.   Oncotarget

Humanization of Antibodies Using Heavy Chain Complementarity-determining Region 3 Grafting Coupled within VitroSomatic Hypermutation

(2013) Peter M. Bowers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY